---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-003387"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T03:58:44.879754+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q1 FY2025 revenue $88.7M (+24% YoY), gross margin 48.3%, net loss narrows to $31.6M

## Summary
- Total revenue $88.7M vs $71.5M YoY; SynBio +28% to $34.4M, NGS +23% to $48.6M.
- Gross margin improved 7.8 points to 48.3% from 40.5% in prior year period.
- Net loss per share ($0.53) vs ($0.75) YoY; adjusted EBITDA ($16.3M) vs ($27.8M).
- FY2025 revenue guidance $372M-$379M; expects gross margin over 50% in Q4 FY2025.
- Cash and short-term investments $270.8M at Dec 31, 2024; shipped to ~2,376 customers.

## SEC filing metadata
- accession: 0001628280-25-003387
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828025003387/0001628280-25-003387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828025003387/twist-20250203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-003387
- JSON: https://secwatch.observer/filing/0001628280-25-003387.json
- Plain text: https://secwatch.observer/filing/0001628280-25-003387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.